<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="/resources/spdi-openaccess-jats.xsl"?>
<!DOCTYPE response [
	
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<!ENTITY % book-part-wrapper SYSTEM "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
	]><response><apiMessage>This XML was provided by Springer Nature</apiMessage><query>doi:10.1186/s13104-019-4572-x</query><apiKey>6b19ee21fe6a243741a528650f7c8997</apiKey><result><total>1</total><start>1</start><pageLength>1</pageLength><recordsDisplayed>1</recordsDisplayed></result><records><article dtd-version="1.2" article-type="brief-report" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="publisher-id">13104</journal-id><journal-title-group><journal-title>BMC Research Notes</journal-title><abbrev-journal-title abbrev-type="publisher">BMC Res Notes</abbrev-journal-title></journal-title-group><issn pub-type="epub">1756-0500</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">s13104-019-4572-x</article-id><article-id pub-id-type="manuscript">4572</article-id><article-id pub-id-type="doi">10.1186/s13104-019-4572-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Note</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Antimicrobial stewardship effectiveness on rationalizing the use of last line of antibiotics in a short period with limited human resources: a single centre cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="Au1"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7893-786X</contrib-id><name><surname>Kuruc Poje</surname><given-names>Darija</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="corresp" rid="IDs131040194572x_cor1">a</xref></contrib><contrib contrib-type="author" id="Au2"><name><surname>Mađarić</surname><given-names>Vesna</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" id="Au3"><name><surname>Janeš Poje</surname><given-names>Vlatka</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au4"><name><surname>Kifer</surname><given-names>Domagoj</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="Au5"><name><surname>Howard</surname><given-names>Philip</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" id="Au6"><name><surname>Marušić</surname><given-names>Srećko</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution content-type="org-division">Hospital Pharmacy Ward</institution><institution content-type="org-name">General Hospital “Dr. Tomislav Bardek”</institution></institution-wrap><addr-line content-type="street">Željka Selingera 1</addr-line><addr-line content-type="postcode">48 000</addr-line><addr-line content-type="city">Koprivnica</addr-line><country country="HR">Croatia</country></aff><aff id="Aff2"><label>2</label><institution-wrap><institution content-type="org-division">Pulmology and Infectology Ward</institution><institution content-type="org-name">General Hospital “Dr. Tomislav Bardek”</institution></institution-wrap><addr-line content-type="street">Željka Selingera 1</addr-line><addr-line content-type="postcode">48 000</addr-line><addr-line content-type="city">Koprivnica</addr-line><country country="HR">Croatia</country></aff><aff id="Aff3"><label>3</label><institution-wrap><institution content-type="org-division">Clinical Microbiology Ward</institution><institution content-type="org-name">Department of Public Health Koprivnica County</institution></institution-wrap><addr-line content-type="street">Željka Selingera 1</addr-line><addr-line content-type="postcode">48 000</addr-line><addr-line content-type="city">Koprivnica</addr-line><country country="HR">Croatia</country></aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0657 4636</institution-id><institution-id institution-id-type="GRID">grid.4808.4</institution-id><institution content-type="org-division">Department of Biophysics, Faculty of Pharmacy and Biochemistry</institution><institution content-type="org-name">University of Zagreb</institution></institution-wrap><addr-line content-type="street">A Kovačića 1</addr-line><addr-line content-type="postcode">10 000</addr-line><addr-line content-type="city">Zagreb</addr-line><country country="HR">Croatia</country></aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8403</institution-id><institution-id institution-id-type="GRID">grid.9909.9</institution-id><institution content-type="org-division">Leeds Institute of Diagnostics and Therapeutics, Faculty of Medicine and Health</institution><institution content-type="org-name">University of Leeds</institution></institution-wrap><addr-line content-type="postcode">LS2 9JT</addr-line><addr-line content-type="city">Leeds</addr-line><country country="GB">UK</country></aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0631 385X</institution-id><institution-id institution-id-type="GRID">grid.412095.b</institution-id><institution content-type="org-division">Department of Endocrinology, Diabetes and Metabolic Diseases</institution><institution content-type="org-name">Clinical Hospital Dubrava</institution></institution-wrap><addr-line content-type="street">Avenija Gojka Šuška 6</addr-line><addr-line content-type="postcode">10 000</addr-line><addr-line content-type="city">Zagreb</addr-line><country country="HR">Croatia</country></aff></contrib-group><author-notes><corresp id="IDs131040194572x_cor1"><label>a</label><email>darijakuruc21@gmail.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>8</month><year>2019</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2019</year></pub-date><volume>12</volume><issue seq="531">1</issue><elocation-id>531</elocation-id><history><date date-type="registration"><day>13</day><month>8</month><year>2019</year></date><date date-type="received"><day>17</day><month>7</month><year>2019</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2019</year></date><date date-type="online"><day>20</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>© The Author(s) 2019</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/" ext-link-type="url">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1" xml:lang="en"><title>Abstract</title><sec id="ASec1"><title>Objective</title><p id="Par1">Antibiotics reserve (ARs) are given as a last line of treatment when other antibiotics are no longer effective. Rising threat of antimicrobial resistance makes growing use of ARs a real problem to patient safety. A single centre interventional cohort study was conducted in order to measure impact on clinical outcomes of A-team programme with limited human resources in a short period. A-team programme started on 01. September 2017.</p></sec><sec id="ASec2"><title>Results</title><p id="Par2">In 3 months preintervention and 3 months intervention period, from 3038 and 3156 hospitalized adult patients, 249 (59% of them were male, median age = 69 years) and 96 (51% of them were male, median age = 70 years) received parenteral ARs. Total duration of hospitalization of patients on AR was reduced from 28 to 17 days of hospitalization on 100 patient-days (OR = 1.92; 95% CI 1.83–2.01; p &lt; 0.001) with no statistical significant difference in rehospitalisation due to infection of patients that were treated with ARs within 2 months after discharge. Despite short period of time and limited human resources, A-team restrictive interventions rationalised parenteral AR use and led to positive impact on clinical outcomes. These results could help our and other A-teams in similar situation in continuing with the programme to bring more evidence.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antibiotic reserve</kwd><kwd>Antimicrobial stewardship</kwd><kwd>Multidisciplinary approach</kwd><kwd>Limited human resources</kwd><kwd>Croatia</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>publisher-imprint-name</meta-name><meta-value>BioMed Central</meta-value></custom-meta><custom-meta><meta-name>volume-issue-count</meta-name><meta-value>1</meta-value></custom-meta><custom-meta><meta-name>issue-article-count</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-pricelist-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-holder</meta-name><meta-value>The Author(s)</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-contains-esm</meta-name><meta-value>No</meta-value></custom-meta><custom-meta><meta-name>article-numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-month</meta-name><meta-value>8</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-day</meta-name><meta-value>13</meta-value></custom-meta><custom-meta><meta-name>article-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>volume-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>journal-product</meta-name><meta-value>ArchiveJournal</meta-value></custom-meta><custom-meta><meta-name>numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-grants-type</meta-name><meta-value>OpenChoice</meta-value></custom-meta><custom-meta><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/13104_2019_Article_4572.pdf</meta-value></custom-meta><custom-meta><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta><custom-meta><meta-name>issue-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>article-type</meta-name><meta-value>BriefCommunication</meta-value></custom-meta><custom-meta><meta-name>journal-subject-primary</meta-name><meta-value>Biomedicine</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Biomedicine, general</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Medicine/Public Health, general</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Life Sciences, general</meta-value></custom-meta><custom-meta><meta-name>journal-subject-collection</meta-name><meta-value>Biomedical and Life Sciences</meta-value></custom-meta><custom-meta><meta-name>open-access</meta-name><meta-value>true</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par11">With estimated 10 million deaths until 2050, antimicrobial resistance (AMR) will reach the first place of main cause of deaths, before deaths from carcinoma or diabetes [<xref ref-type="bibr" rid="CR1">1</xref>]. In addition to slow development of new antimicrobial drugs, these led to creation of list of priority pathogens by World Health Organization (WHO) to support research of new and effective drugs [<xref ref-type="bibr" rid="CR2">2</xref>]. Moreover, to preserve existing antibiotics, WHO also updated their Essential Medicines List for antibiotics, and designated all drugs into access (first line choice), watch and reserve (last line antibiotics). Antibiotic reserves (ARs) should be given as the last line of treatment when other antibiotics no longer work [<xref ref-type="bibr" rid="CR2">2</xref>]. ARs are useful for a wide range of infections but, because of need to reduce the risk of development of resistance and its relatively high cost, it would be inappropriate to recommend their unrestricted use [<xref ref-type="bibr" rid="CR3">3</xref>]. Despite this, their use and resistance are increasing worldwide [<xref ref-type="bibr" rid="CR4">4</xref>-<xref ref-type="bibr" rid="CR7">7</xref>]. As a result, importance of antimicrobial stewardship teams (A-team) has never been more substantial [<xref ref-type="bibr" rid="CR8">8</xref>-<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par12">A cost–benefit analysis showed that maintaining A-team leads to improvements in quality and cost of care with positive clinical outcomes (i.e. by assuring appropriate treatment), compared with standard of care [<xref ref-type="bibr" rid="CR11">11</xref>]. Additionally, effect of AMR policies seems to be variable. Absence of progress is partly due to insufficient evidence base to inform policymakers about effectiveness, generalizability, and cost-effectiveness of initiatives [<xref ref-type="bibr" rid="CR12">12</xref>]. Despite evidence of benefits of A-team implementation, it has still not been recognized and applied in Croatia. Some reasons: not enough infectious disease (ID) specialists or incorporated clinical microbiologists in majority of hospitals or no clinical pharmacists included in clinical medicine.</p><p id="Par13">In this study, we aimed to determine whether implementation and multidisciplinary approach of A-team, in a short period of time, compared with period without A-team, would rationalize number of patients on parenteral AR, without negatively affecting clinical outcomes in acute secondary care public hospital with before mentioned obstacles. Achieving the goal could make A-team to continue with the programme and serve as example for other hospitals and countries with limited human resources.</p></sec><sec id="Sec2"><title>Main text</title><sec id="Sec3"><title>Methods</title><sec id="Sec4"><title>Study design and setting</title><p id="Par14">This was a single-centred cohort before and after study. The study was performed in 325 adult-bed acute secondary care general hospital “Dr. Tomislav Bardek” Koprivnica, Croatia, across all adult wards which covers area with 115 584 inhabitants [<xref ref-type="bibr" rid="CR13">13</xref>]. Included were all hospitalized patients receiving parenteral ARs which were actively used in hospital and were on basic medical reimbursement list of Croatian health insurance fund (piperacillin/tazobactam, ceftazidime, ceftriaxone, cefepime, meropenem, ertapenem, amikacin, vancomycin and colistin (polymyxin E) as well as ciprofloxacin due to evidence of growing resistance [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Chosen were two periods of 3 months (preintervention period from 01. May 2017 to 31. July 2017 and intervention period from 01. September 2017 to 30. November 2017). The A-team intervention started on 01. September 2017.</p><p id="Par15">A-team consisted of multidisciplinary specialists such as 1 FTE ID specialist, 0.5 FTE clinical microbiologist and 0.5 FTE clinical pharmacist who cooperated on daily basis except after working hours, on weekends and holidays. One FTE is defined as full time equivalent of eight working hours from Monday to Friday. Outside that time, an attending physician (a specialist) could prescribe AR, which was reviewed on the first working day by A-team. In that way, there was no delay in the start of antibiotic treatment.</p><p id="Par16">Criteria proposed by Centre for Disease Control and Prevention for appropriate use of antibiotics in hospital settings were described in Standard operative procedure and followed [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p></sec><sec id="Sec5"><title>Type and target of the intervention</title><p id="Par17">We chose restrictive intervention due to evidence of more significant immediate effect on prescribing than education and persuasion interventions [<xref ref-type="bibr" rid="CR18">18</xref>]. It included: a review of medical record by A-team, an interpretation of laboratory susceptibilities from clinical microbiologist, prior audit of ID specialist (bedside consultation) with validation and authorization of prescriptions by clinical pharmacist. The criteria for prescribing AR were: patients with symptoms that were significant or severe (with median definition of fever ≥ 37.5 °C [<xref ref-type="bibr" rid="CR19">19</xref>]), high risk of complications or the infection is not resolving. This recommendation was communicated to treating physicians, but final commitment of implementing clinical decisions was the responsibility of the treating team. A recommendation was also documented in the medical record.</p></sec><sec id="Sec6"><title>Inclusion and exclusion criteria</title><p id="Par18">All adult inpatients who received parenteral AR were included in the study. Exclusion criteria were patients already under the care of ID physician, being treated in preintervention period or paediatric patients.</p></sec><sec id="Sec7"><title>Assessment of the outcomes</title><p id="Par19">Primary outcomes were number, proportion of patients with ARs prescribed and total duration of hospitalization of patients on ARs per 100 patient days. The number of rehospitalized patients due to infection which were previously treated with AR in 1st, 2nd and 3rd month after discharge was also investigated. Diagnoses for the infection were following according to WHO International Statistical Classification of Diseases and Related Health Problems ICD-10 descriptive codes (ICD) [<xref ref-type="bibr" rid="CR20">20</xref>]: diseases of respiratory system (J00-J99) and certain infectious and parasitic diseases (A00-B99). Empirical usage and therapeutic medication were not distinguished in this study. Data were collected monthly from hospital computer system.</p><p id="Par20">Secondary outcomes were the duration of treatment with AR prescribed per 100 patient days. Demographic information (age, gender, main ICD at hospital admission, presence of fever, comorbidities and admitted ward) was obtained to assess risk factors for starting AR.</p></sec><sec id="Sec8"><title>Preintervention period</title><p id="Par21">Preintervention period consisted of prescribing ARs on AR computer ordered form in all adult wards. Physician authorized for prescribing AR filled AR form with basic information on patient and drug (patient′s name and date of birth, working diagnosis, name of AR and daily dosage). This authorization was sent in printed form to the hospital pharmacy. The pharmacist and an experienced pharmacy technician checked the validity and dispensed AR for 2 or 3 days of therapy. Every further prolongation of AR therapy required a new authorization by authorized physician and validation from a pharmacist. The pharmacist did not have access to medical record for further information (e.g., allergy)<italic>.</italic></p><p id="Par22">Preintervention period targeted at the same ARs with the same criteria for prescribing and same primary and secondary outcomes but without A-team.</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par23">Patient characteristics in both periods were compared using Wilcoxon rank-sum test for continuous variables and Fisher exact test for binary categorical variables.</p><p id="Par24">The number of rehospitalization due to infection after 1, 2 and 3 months of discharge were compared using Fisher exact test. Duration of hospitalization of patients on AR and average duration under AR treatment were compared using a Chi-squared test.</p><p id="Par25">All p values only less than 0.05 were considered statistically significant. Statistical analysis was performed in R, version 3.4.4. [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Patient characteristics</title><p id="Par26">Baseline characteristics are shown in Table <xref rid="Tab1" ref-type="table">1</xref>. There was no statistically significant difference between baseline characteristics of proportion of patients on ARs in both periods. Median ages of patients on AR were 69 and 70 years in preintervention and intervention period. Most patients on AR had fever and were admitted to Intensive care unit (ICU) with no statistical difference in comorbidities and main ICD diagnosis on admission in both periods.<table-wrap id="Tab1"><label>Table 1</label><caption xml:lang="en"><p>Characteristics of patients to whom were prescribed antibiotics reserves (ARs) in pre- and intervention period</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Variable</p></th><th align="left"><p>Preintervention period<sup>a</sup></p></th><th align="left"><p>Intervention period<sup>a</sup></p></th><th align="left"><p>p</p></th></tr></thead><tbody><tr><td align="left"><p>N on AR/overall N</p></td><td char="(" align="char"><p>249/3038 (8%)</p></td><td char="(" align="char"><p>96/3156 (3%)</p></td><td char="." align="char"><p>&lt; 0.001</p></td></tr><tr><td align="left"><p>Bed-days on AR/overall bed-days</p></td><td char="(" align="char"><p>3701/20,902 (18%)</p></td><td char="(" align="char"><p>1683/20,722 (8%)</p></td><td char="." align="char"><p>&lt; 0.001</p></td></tr><tr><td align="left"><p>Age, median (min–max)</p></td><td char="(" align="char"><p>69 (19–93)</p></td><td char="(" align="char"><p>70 (20–89)</p></td><td char="." align="char"><p>0.240</p></td></tr><tr><td align="left"><p>Male sex</p></td><td char="(" align="char"><p>146 (59%)</p></td><td char="(" align="char"><p>49 (51%)</p></td><td char="." align="char"><p>0.851</p></td></tr><tr><td align="left" colspan="4"><p>Admitted ward</p></td></tr><tr><td align="left"><p> Internal</p></td><td char="(" align="char"><p>190 (76%)</p></td><td char="(" align="char"><p>68 (71%)</p></td><td char="." align="char"><p>0.530</p></td></tr><tr><td align="left"><p> Intensive care unit (ICU)</p></td><td char="(" align="char"><p>32 (13%)</p></td><td char="(" align="char"><p>13 (14%)</p></td><td char="." align="char"><p>0.106</p></td></tr><tr><td align="left"><p> Surgery</p></td><td char="(" align="char"><p>18 (7%)</p></td><td char="(" align="char"><p>13 (14%)</p></td><td char="." align="char"><p>0.013</p></td></tr><tr><td align="left"><p> Neurology</p></td><td char="(" align="char"><p>7 (3%)</p></td><td char="(" align="char"><p>2 (2%)</p></td><td char="." align="char"><p>1.000</p></td></tr><tr><td align="left"><p> Psychiatry</p></td><td char="(" align="char"><p>2 (1%)</p></td><td char="(" align="char"><p>0 (0%)</p></td><td char="." align="char"><p>1.000</p></td></tr><tr><td align="left"><p>Fever</p></td><td char="(" align="char"><p>173 (72%)</p></td><td char="(" align="char"><p>70 (73%)</p></td><td char="." align="char"><p>0.350</p></td></tr><tr><td align="left"><p>Comorbidities</p></td><td char="(" align="char"><p>226 (91%)</p></td><td char="(" align="char"><p>87 (94%)</p></td><td char="." align="char"><p>0.931</p></td></tr><tr><td align="left" colspan="4"><p>Main ICD at hospital admission</p></td></tr><tr><td align="left"><p> Diseases of the respiratory system (J00-J99)</p></td><td char="(" align="char"><p>61 (24%)</p></td><td char="(" align="char"><p>18 (19%)</p></td><td char="." align="char"><p>0.332</p></td></tr><tr><td align="left"><p> Certain infectious and parasitic diseases (A00–B99)</p></td><td char="(" align="char"><p>38 (15%)</p></td><td char="(" align="char"><p>15 (16%)</p></td><td char="." align="char"><p>1.000</p></td></tr><tr><td align="left"><p> Diseases of the digestive system (K00–K93)</p></td><td char="(" align="char"><p>34 (14%)</p></td><td char="(" align="char"><p>12 (12%)</p></td><td char="." align="char"><p>0.863</p></td></tr><tr><td align="left"><p> Malignant neoplasms (C00–C97)</p></td><td char="(" align="char"><p>25 (10%)</p></td><td char="(" align="char"><p>13 (14%)</p></td><td char="." align="char"><p>0.459</p></td></tr><tr><td align="left"><p> Diseases of the genitourinary system (N00–N99)</p></td><td char="(" align="char"><p>21 (8%)</p></td><td char="(" align="char"><p>12 (12%)</p></td><td char="." align="char"><p>0.316</p></td></tr><tr><td align="left"><p> Diseases of the circulatory system (I00–I99)</p></td><td char="(" align="char"><p>27 (11%)</p></td><td char="(" align="char"><p>6 (6%)</p></td><td char="." align="char"><p>0.306</p></td></tr><tr><td align="left"><p> Injuries (S00–T14)</p></td><td char="(" align="char"><p>14 (6%)</p></td><td char="(" align="char"><p>9 (9%)</p></td><td char="." align="char"><p>0.242</p></td></tr><tr><td align="left"><p> Other</p></td><td char="(" align="char"><p>29 (12%)</p></td><td char="(" align="char"><p>11 (11%)</p></td><td char="." align="char"><p>0.143</p></td></tr></tbody></table><table-wrap-foot><p><italic>AR</italic> parenteral antibiotic reserves, <italic>ICD</italic> International Statistical Classification of Diseases and Related Health Problems</p><p><sup>a</sup>All values are absolute frequencies with the percentage in parenthesis if not stated otherwise in a row</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Preintervention and intervention period</title><p id="Par27">In preintervention period, printed forms for all 249 patients were validated and approved. During intervention, A-team evaluated 354 patients of which 96 (27%) consulted on ARs, while in majority (73%) of patients recommended other antibiotic (which was not AR). The acceptance rate was 100% for all evaluated patients.</p></sec><sec id="Sec13"><title>Results on primary outcomes</title><p id="Par28">Results are shown in Table <xref rid="Tab2" ref-type="table">2</xref>. Duration of hospitalization of patients on AR in preintervention and intervention was 28 and 17 days of hospitalization on 100 patient-days (OR = 1.92; 95% CI 1.83–2.01; p &lt; 0.001), respectively.<table-wrap id="Tab2"><label>Table 2</label><caption xml:lang="en"><p>Primary outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Variable</p></th><th align="left"><p>Preintervention period<sup>a</sup></p></th><th align="left"><p>Intervention period<sup>a</sup></p></th><th align="left"><p>p</p></th></tr></thead><tbody><tr><td align="left"><p>N on AR/overall N</p></td><td align="left"><p>249/3038 (8%)</p></td><td align="left"><p>96/3156 (3%)</p></td><td char="." align="char"><p> &lt; 0.001</p></td></tr><tr><td align="left"><p>Duration of hospitalisation of patients on AR on 100 patient days</p></td><td align="left"><p>28</p></td><td align="left"><p>17</p></td><td char="." align="char"><p> &lt; 0.001</p></td></tr><tr><td align="left" colspan="4"><p>Rehospitalization in</p></td></tr><tr><td align="left"><p> 1st month</p></td><td align="left"><p>13/207 (6)</p></td><td align="left"><p>6/75 (8)</p></td><td char="." align="char"><p>0.597</p></td></tr><tr><td align="left"><p> 2nd month</p></td><td align="left"><p>10/203 (5)</p></td><td align="left"><p>7/68 (10)</p></td><td char="." align="char"><p>0.146</p></td></tr><tr><td align="left"><p> 3rd month</p></td><td align="left"><p>6/200 (3)</p></td><td align="left"><p>5/67 (7)</p></td><td char="." align="char"><p>0.033</p></td></tr></tbody></table><table-wrap-foot><p><italic>AR</italic> parenteral antibiotic reserves, <italic>ICD</italic> International Statistical Classification of Diseases and Related Health Problems</p><p><sup>a</sup>All values are absolute frequencies with the percentage in parenthesis if not stated otherwise in a row</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec14"><title>Secondary outcomes</title><p id="Par29">Duration of treatment with AR prescribed in preintervention and intervention periods were 11 and 4 days per 100 patient days (OR = 2.7; 95% CI 2.5–2.9; p &lt; 0.001), respectively. There was no statistical difference in both periods for risk factors for starting AR which were: male patients, median age of 70 years, internal ward admission, fever, existing comorbidities, disease of the respiratory system or certain infectious and parasitic diseases.</p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par30">Despite limited human resources of A-team and a short period, this study showed a significant impact on clinical outcomes, focusing on parenteral ARs. Restrictive interventions helped to save last line antibiotics for their future use when they are really needed. The first A-team in Croatia, which consisted of ID specialist, clinical microbiologist and clinical pharmacist, demonstrated an immediate impact of their interventions. Example is reduction of duration of hospitalization of patients in intervention period by nearly 40% (from 28 to 17 days of hospitalization on 100 patient-days) with unaffected rehospitalizations. This brought highly needed evidence of positive effects of interventions on patient-centred outcomes [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. There was no statistical significance in rehospitalisation of patients on AR due to infection in first 2 months after discharge. However, in the 3rd month after discharge rehospitalisation was raised from 3 to 7% in intervention group which was statistically significant (p = 0.033). One of the reasons could be high risk of mortality due to comorbidity that made patients more vulnerable to influenza in influenza period that had the highest peak during January and February 2018 [<xref ref-type="bibr" rid="CR23">23</xref>]. Winter was monitoring period for intervention group while preintervention group was followed in autumn period, therefore patients had better chance to stay out of hospital. Second argument could be piperacillin 4 g/tazobactam 0.5 g shortage due to production reasons in intervention period, but that needs further investigation [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par31">Complete acceptance rate reflected agreement between A-team, treating physicians and their teams. In addition, this was also in accordance with final step of A-team intervention, which consisted of dispensing AR from hospital pharmacy only after validation from clinical pharmacist with access to medical record. Improving antimicrobial prescribing by clinical pharmacist is in correlation with previous studies and guidelines [<xref ref-type="bibr" rid="CR25">25</xref>-<xref ref-type="bibr" rid="CR27">27</xref>]. Multidisciplinary approach has proved to be beneficial in this study for understanding the A-team interventions and therefore accomplishing primary outcomes. Other studies have also proven importance of multidisciplinary approach but in other areas such as preoperative prophylaxis, broad-spectrum antibiotic consumption in various settings or timeliness of antimicrobial therapy in patients with positive blood cultures [<xref ref-type="bibr" rid="CR28">28</xref>-<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par32">Risk factors for starting AR can be used in hospitals with resource limitation as a measure of estimation of patients that need special attention.</p><p id="Par33">Furthermore, our aim correlates with WHO Global Action Plan on Antimicrobial Resistance to contain antibiotic resistance, optimize antibiotic treatment and to preserve 'last-resort' antibiotics [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par34">This study suggests that A-team restrictive interventions focused on parenteral ARs are useful strategy in improving antimicrobial prescribing without compromising clinical outcomes. Moreover, we proved possibility of achieving our goals despite limited human resources and short period. In addition, results could serve as evidence for including clinical pharmacists in clinical medicine in Croatia. Our research demonstrated the best practice that could be transferred to other national and transnational institutions.</p></sec></sec><sec id="Sec16"><title>Limitations</title><p id="Par35">Study was a single centre non-randomized study, which was the first limitation. However, it was difficult to blind investigators or participants in trial of antimicrobial stewardship. Second limitation was two periods of 3 months which were short to prove sustainability, but we demonstrated A-team programme's value by focusing on outcome measures. Third, A-team just focused on AR and not on other antibiotics, which should be investigated in future studies. Nonetheless, we wanted to investigate the effectiveness of A-team on a small but very important group of antibiotics that are costly and under restricted use. In addition, the aim was to show our positive results to managers who could give us more resources to broaden our interventions to other classes of antimicrobials. Finally, we did not investigate AMR due to too short period of follow up, but this is our plan for future.</p><p id="Par36">The future research is needed with a larger multi-centred study, more extended period of intervention, follow up and feedback of A-team with particular emphasis on effectiveness of clinical pharmacy services.</p></sec></body><back><ack><title>Acknowledgements</title><p>We would like to thank all who supported the implementation of antimicrobial stewardship team in our hospital.</p></ack><sec sec-type="author-contribution"><title>Authors’ contributions</title><p>Each author (DKP, VM, VJP, DK, PH and SM) had substantial contributions to the conception or design of the work, analysis, interpretation of data, substantively revised it and have approved the submitted version (and any substantially modified version that involves the author's contribution to the study). All authors have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the authors were not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. All authors read and approved the final manuscript.</p></sec><sec><title>Funding</title><p>The author received no specific funding for this work.</p></sec><sec sec-type="data-availability"><title>Availability of data and materials</title><p>The data that support the findings of this study are available from general hospital “Dr. Tomislav Bardek” Koprivnica, Croatia but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of general hospital “Dr. Tomislav Bardek” Koprivnica, Croatia.</p></sec><sec sec-type="ethics-statement"><sec><title>Ethics approval and consent to participate</title><p>Approval from Ethics committee from hospital “Dr. Tomislav Bardek” Koprivnica was obtained with identification numbers: 053-02/18-01/33 and 2137-15-01-18-02. As prescribing AR and other antibiotics before and after implementation of A-team were considered as routine care, and because both interventions were associated with minimal risk to patients, the need for consent to participate was waived (according to The Patient Rights Protection Act, legislation number NN 169/04, 37/08). All participant information obtained during the study was kept confidential.</p></sec><sec><title>Consent for publication</title><p>Not applicable.</p></sec><sec sec-type="COI-statement"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec></sec><ref-list id="Bib1"><title>References</title><ref-list><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Resist. 2014; p. 1–18. <ext-link xlink:href="https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf" ext-link-type="url">https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf</ext-link>. Accessed 5 Feb 2019.</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Geneva: World Health Organization; 2017. p. 1–88. <ext-link xlink:href="https://www.who.int/medicines/areas/rational_use/PPLreport_2017_09_19.pdf" ext-link-type="url">https://www.who.int/medicines/areas/rational_use/PPLreport_2017_09_19.pdf</ext-link>. Accessed 5 Feb 2019.</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">World Health Organization. Chapter 9. Reserve anti-infective agents. In: The use of essential drugs: ninth report of the WHO expert committee. Geneva: World Health Organization; 2000. p. 1–68. <ext-link xlink:href="https://apps.who.int/iris/bitstream/handle/10665/42373/WHO_TRS_895.pdf;jsessionid=61A739599D18D39C99AA7AF582F92D34?sequence=1" ext-link-type="url">https://apps.who.int/iris/bitstream/handle/10665/42373/WHO_TRS_895.pdf;jsessionid=61A739599D18D39C99AA7AF582F92D34?sequence=1</ext-link>. Accessed 13 Aug 2017.</mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meletis</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Carbapenem resistance: an overview of the problem and future perspectives</article-title><source>Ther Adv Infect Dis</source><year>2016</year><volume>3</volume><issue>1</issue><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2sXisFWhu7g%3D</pub-id><pub-id pub-id-type="pmid">26862399</pub-id><pub-id pub-id-type="pmcid">4735501</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Codjoe</surname><given-names>FS</given-names></name><name><surname>Donkor</surname><given-names>ES</given-names></name></person-group><article-title xml:lang="en">Carbapenem resistance: a review</article-title><source>Med Sci</source><year>2018</year><volume>6</volume><issue>1</issue><fpage>1</fpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1MXms12ms7Y%3D</pub-id><pub-id pub-id-type="doi">10.3390/medsci6010001</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuinness</surname><given-names>WA</given-names></name><name><surname>Malachowa</surname><given-names>N</given-names></name><name><surname>DeLeo</surname><given-names>FR</given-names></name></person-group><article-title xml:lang="en">Vancomycin Resistance in <italic>Staphylococcus aureus</italic></article-title><source>Yale J Biol Med</source><year>2017</year><volume>90</volume><issue>2</issue><fpage>269</fpage><lpage>281</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1MXhslOktr0%3D</pub-id><pub-id pub-id-type="pmid">28656013</pub-id><pub-id pub-id-type="pmcid">5482303</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>MS</given-names></name><name><surname>Tolmasky</surname><given-names>ME</given-names></name></person-group><article-title xml:lang="en">Amikacin: uses, resistance, and prospects for inhibition</article-title><source>Molecules</source><year>2017</year><volume>22</volume><fpage>2267</fpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1cXhvVKqs7k%3D</pub-id><pub-id pub-id-type="doi">10.3390/molecules22122267</pub-id><pub-id pub-id-type="pmcid">5889950</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberjé</surname><given-names>EJM</given-names></name><name><surname>Tanke</surname><given-names>MAC</given-names></name><name><surname>Jeurissen</surname><given-names>PPT</given-names></name></person-group><article-title xml:lang="en">Antimicrobial stewardship initiatives throughout Europe: proven value for money</article-title><source>Infect Dis Rep</source><year>2017</year><volume>9</volume><issue>1</issue><fpage>6800</fpage><pub-id pub-id-type="doi">10.4081/idr.2017.6800</pub-id><pub-id pub-id-type="pmid">28458794</pub-id><pub-id pub-id-type="pmcid">5391535</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">European Centre for Disease Prevention and Control. Infographics about antibiotic stewardship programmes. <ext-link xlink:href="https://antibiotic.ecdc.europa.eu/en/infographics-about-antibiotic-stewardship-programmes" ext-link-type="url">https://antibiotic.ecdc.europa.eu/en/infographics-about-antibiotic-stewardship-programmes</ext-link>. Accessed 15 July 2019.</mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey</surname><given-names>P</given-names></name><name><surname>Marwick</surname><given-names>CA</given-names></name><name><surname>Scott</surname><given-names>CL</given-names></name><name><surname>Charani</surname><given-names>E</given-names></name><name><surname>McNeil</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>E</given-names></name><etal/></person-group><article-title xml:lang="en">Interventions to improve antibiotic prescribing practices for hospital inpatients</article-title><source>Cochrane Database Syst Rev</source><year>2017</year><pub-id pub-id-type="doi">10.1002/14651858.CD003543.pub4</pub-id><pub-id pub-id-type="pmid">28178770</pub-id><pub-id pub-id-type="pmcid">6472528</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheetz</surname><given-names>MH</given-names></name><name><surname>Bolon</surname><given-names>MK</given-names></name><name><surname>Postelnick</surname><given-names>M</given-names></name><name><surname>Noskin</surname><given-names>GA</given-names></name><name><surname>Lee</surname><given-names>TA</given-names></name><etal/></person-group><article-title xml:lang="en">Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis</article-title><source>J Antimicrob Chemother</source><year>2009</year><volume>63</volume><issue>4</issue><fpage>816</fpage><lpage>25</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD1MXjt1Gjsbc%3D</pub-id><pub-id pub-id-type="doi">10.1093/jac/dkp004</pub-id><pub-id pub-id-type="pmid">19202150</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dar</surname><given-names>OA</given-names></name><name><surname>Hasan</surname><given-names>R</given-names></name><name><surname>Schlundt</surname><given-names>J</given-names></name><name><surname>Harbarth</surname><given-names>S</given-names></name><name><surname>Caleo</surname><given-names>G</given-names></name><name><surname>Dar</surname><given-names>FK</given-names></name><etal/></person-group><article-title xml:lang="en">Exploring the evidence base for national and regional policy interventions to combat resistance</article-title><source>Lancet</source><year>2016</year><volume>387</volume><issue>10015</issue><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)00520-6</pub-id><pub-id pub-id-type="pmid">26603921</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Croatian Bureau of statistics. Population census 2011. Croatian Bureau of statistics, Zagreb; 2013. <ext-link xlink:href="https://www.dzs.hr/Eng/censuses/census2011/results/htm/e01_01_03/e01_01_03.html" ext-link-type="url">https://www.dzs.hr/Eng/censuses/census2011/results/htm/e01_01_03/e01_01_03.html</ext-link>. Accessed 15 Sept 2017.</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Hrvatski zavod za zdravstveno osiguranje. Objavljene liste lijekova. Osnovna lista lijekova; 2017. <ext-link xlink:href="https://www.hzzo.hr/zdravstveni-sustav-rh/trazilica-za-lijekove-s-vazecih-lista/arhiva-liste-lijekova/" ext-link-type="url">https://www.hzzo.hr/zdravstveni-sustav-rh/trazilica-za-lijekove-s-vazecih-lista/arhiva-liste-lijekova/</ext-link>. Accessed 6 Aug 2019.</mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasugba</surname><given-names>O</given-names></name><name><surname>Gardner</surname><given-names>A</given-names></name><name><surname>Mitchell</surname><given-names>BG</given-names></name><name><surname>Mnatzaganian</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies</article-title><source>BMC Infect Dis.</source><year>2015</year><volume>15</volume><fpage>545</fpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2sXkt1OhsQ%3D%3D</pub-id><pub-id pub-id-type="doi">10.1186/s12879-015-1282-4</pub-id><pub-id pub-id-type="pmid">26607324</pub-id><pub-id pub-id-type="pmcid">4660780</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention (CDC). Core elements of hospital antibiotic stewardship programs. Atlanta, GA: US Department of Health and Human Services, CDS; 2014. p. 1–24. <ext-link xlink:href="https://www.cdc.gov/antibiotic-use/healthcare/pdfs/core-elements.pdf" ext-link-type="url">https://www.cdc.gov/antibiotic-use/healthcare/pdfs/core-elements.pdf</ext-link>. Accessed 2 June 2017.</mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Mađarić V. Upravljanje primjenom antimikrobnih lijekova u OB Koprivnica—antibiotic stewardship program. Standardni operativni postupak, Koprivnica, Croatia 2017. p 1–25. Internal document for Standard operative procedure in Croatian language: available upon request.</mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>E</given-names></name><name><surname>Charani</surname><given-names>E</given-names></name><name><surname>Fenelon</surname><given-names>L</given-names></name><name><surname>Gould</surname><given-names>IM</given-names></name><name><surname>Holmes</surname><given-names>A</given-names></name><etal/></person-group><article-title xml:lang="en">Interventions to improve antibiotic prescribing practices for hospital inpatients</article-title><source>Cochrane Database Syst Rev.</source><year>2013</year><volume>30</volume><issue>4</issue><fpage>CD003543</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD003543.pub3</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Dinarello CA, Porat R. Fever. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J, Kasper D, et al. editors. Harrison’s principles of internal medicine, 19e. New York: McGraw-Hill; 2014. p. 23. <ext-link xlink:href="https://accessmedicine.mhmedical.com/content.aspx%3Fbookid=1130%A7ionid=79724479" ext-link-type="url">https://accessmedicine.mhmedical.com/content.aspx?bookid=1130§ionid=79724479</ext-link>. Accessed 23 June 2017.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>International statistical classification of diseases and related health problems—10th revision 2016 v.3</source><year>2015</year><edition>5</edition><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Core Team. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018. <ext-link xlink:href="https://www.r-project.org/" ext-link-type="url">https://www.r-project.org/</ext-link>. Accessed 18 Apr 2019.</mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Filice</surname><given-names>G</given-names></name><name><surname>Drekonja</surname><given-names>D</given-names></name><name><surname>Greer</surname><given-names>N</given-names></name><name><surname>Butler</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>B</given-names></name><name><surname>MacDonald</surname><given-names>R</given-names></name><etal/></person-group><source>Antimicrobial stewardship programs in inpatient settings: a systematic review, Summary and discussion</source><year>2013</year><publisher-loc>Washington</publisher-loc><publisher-name>Department of Veterans Affairs (US)</publisher-name></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">European Centre for Disease Prevention and Control. Flu News Europe: weekly influenza updates 2018. In collaboration with WHO Regional Office for Europe, ECDC monitors and reports on influenza activity in Europe on a weekly basis throughout the flu season. <ext-link xlink:href="https://ecdc.europa.eu/en/seasonal-influenza/surveillance-and-disease-data/flu-news-europe" ext-link-type="url">https://ecdc.europa.eu/en/seasonal-influenza/surveillance-and-disease-data/flu-news-europe</ext-link>. Accessed 29 Apr 2018.</mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Agency for medical products and medical devices of Croatia. Shortages and disruption in the supply chain. Nestašice lijekova. <ext-link xlink:href="https://www.halmed.hr/en/Promet-proizvodnja-i-inspekcija/Promet/Prekid-opskrbe-trzista-lijekom-i-nestasice/" ext-link-type="url">https://www.halmed.hr/en/Promet-proizvodnja-i-inspekcija/Promet/Prekid-opskrbe-trzista-lijekom-i-nestasice/</ext-link>. Accessed 15 Mar 2018.</mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubrovskaya</surname><given-names>Y</given-names></name><name><surname>Scipione</surname><given-names>MR</given-names></name><name><surname>Siegfried</surname><given-names>J</given-names></name><name><surname>Jen</surname><given-names>SP</given-names></name><name><surname>Pham</surname><given-names>V</given-names></name><name><surname>Papadopoulos</surname><given-names>J</given-names></name><etal/></person-group><article-title xml:lang="en">Multilayer model of pharmacy participation in the antimicrobial stewardship program at a large academic medical center</article-title><source>Hosp Pharm</source><year>2017</year><volume>52</volume><issue>9</issue><fpage>628</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1177/0018578717726993</pub-id><pub-id pub-id-type="pmid">29276300</pub-id><pub-id pub-id-type="pmcid">5735737</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilchrist</surname><given-names>M</given-names></name><name><surname>Wade</surname><given-names>P</given-names></name><name><surname>Ashiru-Oredope</surname><given-names>D</given-names></name><name><surname>Howard</surname><given-names>P</given-names></name><name><surname>Sneddon</surname><given-names>J</given-names></name><name><surname>Whitney</surname><given-names>L</given-names></name><name><surname>Wickens</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">Antimicrobial stewardship from policy to practice: experiences from UK antimicrobial pharmacists</article-title><source>Infect Dis Ther</source><year>2015</year><volume>4</volume><issue>Suppl 1</issue><fpage>51</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1007/s40121-015-0080-z</pub-id><pub-id pub-id-type="pmid">26362295</pub-id><pub-id pub-id-type="pmcid">4569645</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De With</surname><given-names>K</given-names></name><name><surname>Allerberger</surname><given-names>F</given-names></name><name><surname>Amann</surname><given-names>S</given-names></name><name><surname>Apfalter</surname><given-names>P</given-names></name><name><surname>Brodt</surname><given-names>HR</given-names></name><name><surname>Eckmanns</surname><given-names>T</given-names></name><etal/></person-group><article-title xml:lang="en">Strategies to enhance rational use of antibiotics in hospital: a guideline by the German society for infectious diseases</article-title><source>Infection</source><year>2016</year><volume>44</volume><fpage>395</fpage><lpage>439</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28XmtVantrc%3D</pub-id><pub-id pub-id-type="doi">10.1007/s15010-016-0885-z</pub-id><pub-id pub-id-type="pmid">27066980</pub-id><pub-id pub-id-type="pmcid">4889644</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paskovaty</surname><given-names>A</given-names></name><name><surname>Pflomm</surname><given-names>JM</given-names></name><name><surname>Myke</surname><given-names>N</given-names></name><name><surname>Seo</surname><given-names>SK</given-names></name></person-group><article-title xml:lang="en">A multidisciplinary approach to antimicrobial stewardship: evolution into the 21st century</article-title><source>Int J Antimicrob Agents</source><year>2005</year><volume>25</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD2cXhtFGhsL%2FL</pub-id><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2004.09.001</pub-id><pub-id pub-id-type="pmid">15620820</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>MC</given-names></name><name><surname>Behrens</surname><given-names>SL</given-names></name><name><surname>Webster</surname><given-names>W</given-names></name><name><surname>Huslage</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>BA</given-names></name><name><surname>Wrenn</surname><given-names>R</given-names></name><etal/></person-group><article-title xml:lang="en">Multidisciplinary approach to <italic>Clostridium difficile</italic> infection in adult surgical patients</article-title><source>J Am Coll Surg</source><year>2019</year><volume>228</volume><issue>4</issue><fpage>570</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2018.12.045</pub-id><pub-id pub-id-type="pmid">30739011</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>SJ</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>JI</given-names></name><name><surname>Majid</surname><given-names>AM</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Efird</surname><given-names>L</given-names></name><etal/></person-group><article-title xml:lang="en">Impact of hospitalist-led interdisciplinary antimicrobial stewardship interventions at an academic medical center</article-title><source>JtComm J Qual Patient Saf</source><year>2019</year><volume>45</volume><issue>3</issue><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.jcjq.2018.09.002</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cairns</surname><given-names>Kelly A</given-names></name><name><surname>Doyle</surname><given-names>Joseph S</given-names></name><name><surname>Trevillyan</surname><given-names>Janine M</given-names></name><name><surname>Horne</surname><given-names>Kylie</given-names></name><name><surname>Stuart</surname><given-names>Rhonda L</given-names></name><etal/></person-group><article-title xml:lang="en">The impact of a multidisciplinary antimicrobial stewardship team on the timeliness of antimicrobial therapy in patients with positive blood cultures: a randomized controlled trial</article-title><source>J Antimicrobial Chemother</source><year>2016</year><volume>71</volume><issue>11</issue><fpage>3276</fpage><lpage>3283</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28XitFaksrfM</pub-id><pub-id pub-id-type="doi">10.1093/jac/dkw285</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">World Health Organization. Global action plan on antimicrobial resistance. Geneva: World Health Organization; 2015. p. 1–28. <ext-link xlink:href="https://www.wpro.who.int/entity/drug_resistance/resources/global_action_plan_eng.pdf" ext-link-type="url">https://www.wpro.who.int/entity/drug_resistance/resources/global_action_plan_eng.pdf</ext-link>. Accessed 17 Apr 2019.</mixed-citation></ref></ref-list></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>A-team</term><def><p id="Par3">antimicrobial stewardship team</p></def></def-item><def-item><term>AMR</term><def><p id="Par4">antimicrobial resistance</p></def></def-item><def-item><term>AR</term><def><p id="Par5">antibiotic reserve</p></def></def-item><def-item><term>FTE</term><def><p id="Par6">full time equivalent</p></def></def-item><def-item><term>ICD</term><def><p id="Par7">International Statistical Classification of Diseases and Related Health Problems</p></def></def-item><def-item><term>ICU</term><def><p id="Par8">intensive care unit</p></def></def-item><def-item><term>ID</term><def><p id="Par9">infectious disease</p></def></def-item><def-item><term>WHO</term><def><p id="Par10">World Health Organization</p></def></def-item></def-list></glossary><notes notes-type="Misc"><title>Publisher's Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></notes></back></article></records><facets><facet name="subject"><facet-value count="1">Biomedicine</facet-value><facet-value count="1">Biomedicine, general</facet-value><facet-value count="1">Life Sciences, general</facet-value><facet-value count="1">Medicine/Public Health, general</facet-value></facet><facet name="keyword"><facet-value count="1">Antibiotic reserve</facet-value><facet-value count="1">Antimicrobial stewardship</facet-value><facet-value count="1">Croatia</facet-value><facet-value count="1">Limited human resources</facet-value><facet-value count="1">Multidisciplinary approach</facet-value></facet><facet name="pub"><facet-value count="1">BMC Research Notes</facet-value></facet><facet name="year"><facet-value count="1">2019</facet-value></facet><facet name="country"><facet-value count="1">Croatia</facet-value><facet-value count="1">United Kingdom</facet-value></facet><facet name="type"><facet-value count="1">Journal</facet-value></facet></facets></response>
